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ABSTRACT 
 
Recently available cancer sequencing data have revealed a complex view of the cancer genome 
containing a multitude of mutations, including drivers responsible for cancer progression and 
neutral passengers. Measuring selection in cancer and distinguishing drivers from passengers have 
important implications for development of novel treatment strategies. It has recently been argued 
that a third of cancers are evolving neutrally, as their mutational frequency spectrum follows a 1/f 
power law expected from neutral evolution in a particular intermediate frequency range. We study 
a stochastic model of cancer evolution and derive a formula for the probability distribution of the 
cancer cell frequency of a subclonal driver, demonstrating that driver frequency is biased towards 
0 and 1. We show that it is difficult to capture a driver mutation at an intermediate frequency, and 
thus the calling of neutrality due to a lack of such driver will significantly overestimate the number 
of neutrally evolving tumors. Our approach provides precise quantification of the validity of the 
1/f statistic across the entire range of all relevant parameter values. We also show that our 
conclusions remain valid for non-exponential models: spatial 3d model and sigmoidal growth, 
relevant for early- and late stages of cancer growth. 
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AUTHOR SUMMARY 
 
Darwinian evolution in cancer is responsible for the emergence of malignant traits in initially 
benign tumors. As tumor cells divide, they accumulate new mutations and while most of them are 
“passengers” which do not confer any selective growth advantage, “driver” mutations endow cells 
with traits that contribute to cancer spread. Identifying driver mutations that are under selection in 
cancer can point to new targets for cancer therapeutics and open new avenues for personalized 
cancer treatment. It has recently been argued that the presence or absence of selection in cancer 
can be deduced from deviation of mutant allele frequencies from 1/f power law in an intermediate 
frequency range. Using a stochastic mathematical model of cancer evolution we derive a formula 
for the frequency of a subclonal driver and show that frequencies of cancer drivers are biased 
towards 0 and 1; thus most mutations will inevitably appear to be either neutral (frequency ≈ 0) 
or clonal (frequency ≈ 1) despite very different levels of selection. Consequently, the proposed 
1/f statistic will significantly overestimate the number of cancers deemed to be evolving neutrally. 
Our work quantifies the validity of the proposed neutral evolution statistic across the entire range 
of all relevant parameter values. 
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INTRODUCTION 
 
Darwinian evolution in cancer has been the subject of intense research in the past decade. In 
particular, the problem of distinguishing driver mutations that carry a selective advantage from 
passenger mutations, and their role in shaping intra-tumor genetic heterogeneity has come to the 
fore1-5. Determining which mutations in cancer are drivers and which are passengers is one of the 
most pressing questions in cancer genomics, as identification of new driver mutations can 
contribute to development of new targeted therapeutics6,7 and personalized medicine8. Numerous 
methods for classifying driver and passenger mutations and measuring selection in cancer have 
been developed, including those that identify driver genes based on how frequently they are 
mutated2, specific mutation patterns9,10, and dN/dS ratios1,11. These methods can reliably identify 
driver genes mutated in an high proportion of tumors of a given type (>20%); using such methods 
to find less common drivers would require a large number of cancer samples12, and drivers unique 
to a single or a small number of patients could still be missed.  
 
Several recent papers attempt to measure the magnitude of selection operating during cancer 
evolution using the frequency distribution of subclonal mutations in an individual patient’s cancer. 
In a seminal paper, Williams et al. used mutant allele frequencies to conclude that a significant 
fraction (~1/3) of cancers evolve neutrally13. Subsequent studies focused on quantifying the 
strength of selection and distinguishing it from “effectively neutral” cancer evolution14,15.  These 
works are based upon the assumption that drivers that arose after cancer initiation will be present 
at a macroscopic but clearly subclonal frequency (i.e. “detectable”), which will make the 
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cumulative mutant allele frequency look different to the 1/f power law expected from neutral 
evolution13,15. Here we use a branching process model of cancer evolution to derive a formula for 
the probability of detection of a subclonal driver, and test the validity of the proposed 1/f statistic 
across all relevant parameter combinations.    
 
RESULTS 
 
We consider a two-type stochastic model of cancer evolution (Fig. 1a). In the model, cancer is 
initiated by a single transformed cell. Progeny of this cell follow a branching process with birth 
rate b and death rate d. We set r = b – d > 0, so the population grows if it survives initial stochastic 
fluctuations. In addition, cancer cells can obtain a new driver mutation with rate u (see Materials 
and Methods). Cells with the driver mutation replicate with rate b1 and die with rate d1 smaller than 
b1 (Fig. 1a,b). The subpopulation of driver-carrying cells has therefore a net growth rate r1 = b1 – 
d1, and we assume that r1 > r so that the additional driver increases the net growth rate by the factor 
c = r1/r > 1. We define g = c - 1 as the relative increase in the growth rate due to the driver. 
 
We are interested in the frequency of cancer cells that carry the driver mutation. In a neutral process 
(g = 0), mutation frequency stabilizes and remains approximately constant at large times16. For g 
> 0 (driver with a selective advantage), the frequency of cells with the driver increases from ≈0 to 
≈ 100% during tumor expansion. We denote by 𝐹[𝛼]  the probability that subclonal driver 
frequency f is smaller than 𝛼. We show (Materials and Methods) that this cumulative frequency 
distribution reads 
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𝐹[𝛼] ≈ ∫
𝑐𝑢
𝑏1
𝑀
0
exp (−
𝑐𝑢
𝑏1
𝑋) [1 − exp (−
𝑐𝑟
𝑏1
𝛼
(1 − 𝛼)𝑐
) 𝑋𝑐𝑀1−𝑐] 𝑑𝑋        (1) 
 
where denotes M is number of cells in the tumor. Formula (1) is in excellent agreement with exact 
computer simulations of the branching process (Materials and Methods). Recently, similar two-
type processes were studied by Kessler and Levine17 and Cheek and Antal18, who derived 
generating functions18 and probability distributions for the size of the mutant population in the 
case of small mutant frequencies17 in the general asymmetric (different fitness of wildtype and 
mutant cells) Luria-Delbruck model with death. In contrast, our formula (1) describes the 
probability distribution for a single driver subclone that has reached non-negligible frequencies.  
 
We note that equation (1) concerns the cancer cell frequency of a subclonal driver, and not the 
variant allele frequency obtained from genomic analysis. As noted recently19, variant allele 
frequency does not automatically indicate a certain cancer cell frequency (due to contamination 
with normal cells and variable ploidy), and using allele frequencies instead of cancer cell 
frequencies to detect selection can be an additional source of bias.  
 
We assume that a subclonal driver mutation can be detected, and able to skew the 1/f power law 
expected from neutral evolution, when its cancer cell frequency is between 20% and 80%. This 
range is much wider than the range 24% to 48% used in Williams et al.13 (mutant allele frequency 
range 12% to 24%). Thus, the probability that a driver can be detected is given by 
 
𝑃𝑑𝑒𝑡 = 𝐹[0.8] − 𝐹[0.2]             (2) 
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For moderate levels of selection, e.g., when the additional driver mutation increases the growth 
rate by g = 30%, the probability that the driver mutation is in the detectable range ([0.2,0.8]) is 
<15% for population sizes up to M=109 cells, and remains below one third for 𝑀 ≤ 1011 cells 
(Fig. 2a). For other cases considered here (70% and 100% increase in the net growth rate), the 
chance of detecting the subclonal driver is always <60% and - for a broad range of tumor sizes – 
less than 30%. The parameters used in Fig. 2a are from Bozic et al.20, and are typical for a 
moderately aggressive cancer (net growth rate 0.01/day). We show that the situation is 
qualitatively similar for faster and slower growing cancers in Figs. 2b,c. In summary, for moderate 
levels of selection (g = 30%), the chance of detecting a subclonal driver is small for almost any 
tumor size, and very strong selection (g = 100%) will be detectable only in small cancers. Strong 
selection (g = 70%) will be detectable at intermediate-size, moderately growing tumors; large, fast-
growing tumors; or small, slow-growing tumors. Most notably, for all parameter values, even in 
the parameter regimes where the probability of detecting the subclonal driver is the highest, it is 
still below 60% (Fig. 2a-c). 
 
Our model suggests that detecting deviation from neutral evolution is challenging, as there is a 
significant chance that a subclonal driver will not be in the detectable range. The reason is that the 
frequency of cells with the new driver is biased toward 0 and 1. When the tumor is small, the 
fraction of driver-carrying cells is very close to zero, as there has not yet been enough time for the 
fitter subpopulation to expand (Fig. 2d). In contrast, for large tumors, driver-carrying 
subpopulation has already expanded and completely dominates the population, so its frequency is 
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close to 100% (Fig. 2e). Interestingly, for sizes at which the chance of detecting the subclonal 
driver is highest (close to 60%), the frequency distribution is almost flat (Fig. 2f).  
 
In Fig. 2 we used a previously estimated driver mutation rate u=10-5 per day21. To explore the 
effect of a higher or lower driver mutation rate on our conclusions, we first used recently published 
genomic data to determine an upper bound (10-3) and a lower bound (10-7 per day) on the driver 
mutation rate (Materials and Methods). We next performed a numerical grid search on the space 
of all parameters (driver mutation rate u, relative growth rate advantage of a driver 𝑔, net growth 
rate of tumor cells r, division rate of cells with the driver b1, and final number of tumor cells M). 
A wide range of values is taken for each parameter, including driver mutation rate u between 10-7 
and 10-3 per day, and growth advantage of a subclonal driver 𝑔  between 1% and 200% (see 
Materials and Methods for more details). The grid search demonstrated that the probability of 
detection of a subclonal driver is always below 60%, and that subclonal driver frequency is biased 
towards 0 and 1 across the entire range of reasonable parameter values of the carcinogenic process 
(Materials and Methods, Fig. 3). The intuitive reason behind this result is that the probability 
density function for subclonal driver frequency is convex across this entire parameter range 
(examples in Fig. 2d,e,f). 
 
The well-mixed model discussed so far does not include spatial constrains experienced by solid 
tumors. We thus extended our analysis to a similar two-type process in three dimensional space, 
using a lattice-based computer model5. We considered a version of the model in which cells that 
occupy points of a 3d lattice replicate to empty neighboring sites, die, and mutate, but do not 
migrate5. Normal cells replicate and die with rates 𝑏, 𝑑, whereas mutant cells replicate with rate 𝑏 
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but die with rate d1. Similarly as before, the ratio of net growth rates of cells with and without the 
driver is given by c = 1 + g = (b - d1) / (b - d) >1. To simulate a large number of tumors for realistic 
sizes, we scaled the parameters of the model so that 1 site corresponded to 100 cells, and mutation 
probability was 100x larger.   
 
Supplementary Fig. 1 shows the probability of detection of a subclonal driver as a function of 
tumor size for medium, fast and slow tumor growth, and for three levels of driver potency (g=30%, 
70% and 100% increase in net growth rate b-d). These results demonstrate that our main conclusion 
that many drivers elude detection remains true in the 3d model. In particular, out of 36 parameter 
combinations evaluated, the probability of detection of a subclonal driver was below 60% in 33 
out of 36 cases, and in the remaining 3 cases the probability was 63%, 67% and 68%. The 
probability of detection was 40% or below for one half of the parameter sets. Of note, we observe 
that in the 3d model there is a higher chance of detection of moderate drivers (g=30%) compared 
to the well-mixed model, and the chance of detection peaks at lower tumor sizes compared to the 
well-mixed case.  
 
The growth of tumor populations is complex and may change throughout the carcinogenic process. 
For example, initial growth may be slower than exponential due to tissue constraints and nutrient 
availability, exponential-like after angiogenesis, and may slow down again when the tumor is very 
large. To model this more complex scenario, we use the 3d model described above to model the 
first, avascular stage, before tumor reaches 106 cells22,23. As 106 cells is typically at the lower end 
of tumor detectability, it is unlikely that drivers will be detected at this stage. To model the later 
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stages of tumor growth (exponential and slow-down), we employ the following system of 
differential equations: 
𝑑𝑥
𝑑𝑡
= 𝑟𝑥 (1 −
𝑥 + 𝑦
𝐾
) 
𝑑𝑦
𝑑𝑡
= 𝑐𝑟𝑦 (1 −
𝑥 + 𝑦
𝐾
) 
 
Here x is the size of the type-0 and y is the size of the type-1 (driver) population, c =1+g >1 is the 
ratio of their initial growth rates and K is the carrying capacity of the tumor. We use a deterministic 
model because both wild-type and driver populations are likely to be large at the end of the spatial 
phase. To combine the 3d and the above model, we record the sizes of the type-0 and type-1 
populations obtained from the 3d simulation when total population size reaches 106 cells, and use 
them as initial conditions for the system described above, which we solve numerically. We show 
results for probability of driver detection in this sigmoidal model in Supplementary Fig. 2. 
 
In this sigmoidal growth model, in contrast to the well-mixed and 3d models, driver fraction does 
not approach 1 for large tumors. Instead, it will reach a stable frequency that depends on the initial 
driver fraction and model parameters. For all parameter combinations we evaluated, the chance 
that this final driver frequency is between 0.2 and 0.8 is below 63%. We note that the sigmoidal 
model increases the chance of detection of moderate drivers (g=30%) compared to the well-mixed 
model, but decreases the chance of detection of strong drivers (g=70% and g=100%), as they will 
expand to the carrying capacity quickly and not leave much room for the type-0 population. We 
note that in this model selection will in general be more detectable for slower growing compared 
to faster-growing tumors. In sum, our results imply that in the sigmoidal model, low to moderate 
levels of selection will be most detectable at the final (close to carrying capacity) stage, whereas 
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moderate and strong drivers will be most detectable at the beginning of the exponential-like phase. 
We note, however, that sigmoidal growth models may produce different behaviors depending on 
the specifics of the competition between the two populations – for example not only initial growth 
rates but also the levels of growth inhibition may differ between populations, and cell turnover 
while the population is at carrying capacity may lead to competitive exclusion of the less fit 
population.  
 
Finally, we also considered how adding a second driver within the first driver population would 
influence probability of detection of either driver for realistic parameter values in the well-mixed 
model. To that end, we derived the expression for the probability that the second driver will be in 
the detectable range, assuming the first driver is not detectable, 
𝑃2 ≈ ∫ 𝑓1(𝛼1)(𝐹2(0.8 𝛼1⁄ ) − 𝐹2(0.2 𝛼1⁄ ))𝑑𝛼1
1
0.8
 
Here f1 is the probability density of the first driver frequency (equation (7) in Materials and 
Methods) and F2 is the cumulative probability for the frequency of the second driver in the first 
driver population (equation (1) with appropriate parameter values). 
 
For the same parameters as in Fig. 2, and assuming that second driver increases the net growth rate 
by the same absolute amount as the first, we show that the probability that driver frequency is in 
the range [0.2,0.8] is always below 69% (Supplementary Fig. 3). In addition to this upper bound, 
we also calculate the average probability of driver detection across all parameter values evaluated 
in Supplementary Fig. 3. The average detection probability is 43% when one includes driver 
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mutations in cancer cell frequency (CCF) range [0.2, 0.8]. The average driver detection probability 
for the CCF range [0.24, 0.48] from the original Williams et al. study13 is 18%.   
 
 
DISCUSSION 
 
In sum, the fact that no subclonal driver is present at intermediate frequencies cannot be taken as 
proof of neutral or “effectively” neutral evolution. It can simply be a consequence of population 
dynamics which creates only a short window during which the driver mutation can be detected but 
has not yet dominated the population.  
 
Tarabichi et al.25 and McDonald and colleagues26 simulated tumor evolution in which they 
explicitly include selection, and showed that, even in models with selection, mutant allele 
frequency can exhibit the 1/f power law behavior, resulting in incorrect calling of neutrality. In 
response, Williams and colleagues27,28 argue that the example simulations from Tarabichi et al.25 
and McDonald et al.26 that were incorrectly classified as neutral use extreme parameter values or 
correspond to either strong and early selection (a driver mutant quickly sweeps to fixation), or 
weak and late selection (driver mutants unable to reach detectable frequencies). In contrast, we 
show here that, for almost any driver mutation rate and selection strength, whenever we look at 
the mutant frequency spectrum of a tumor, it is likely either too early and the driver is present at a 
very low frequency, or it is already too late, and the driver is present in almost all cells of the 
tumor. Importantly, even if we manage to obtain the mutant frequency spectrum during the optimal 
window for detection, there is still significant chance (close to half) that the subclonal driver will 
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not be in the detectable range. Thus, even though multiple studies13,29 (including ours16) have 
confirmed that the experimental allele frequency spectrum of many cancers agrees with the 
spectrum of a neutral model in a certain frequency range, we argue that this agreement should not 
be taken as evidence of neutral evolution. 
 
Simulations of branching processes of cancer evolution for realistic tumor sizes and parameter 
values are computationally expensive. To circumvent that, studies often use small population sizes, 
death rate of cancer cells much smaller than the birth rate, and only examine a small set of different 
parameter values. In contrast, our mathematical results (formula 2) can be quickly evaluated for 
realistic parameter values, including all biologically plausible values of selection, mutation, birth 
and death rates, and population size. Furthermore, our results explain why the deviation of the 
mutant allele frequency from the 1/f  power law in an intermediate frequency range is not a 
sensitive statistic for detecting subclonal selection in models of exponentially growing cancer 
populations: mutational frequency distribution of a subclonal driver is convex and thus always 
biased toward 0% or 100% frequency.  
 
In this paper, we study a process in which we explicitly include selection, and show that a subclonal 
driver, though present, may often fail to change the VAF distribution expected from neutral 
evolution. We note that, if there is no subclonal driver present, i.e. when driver mutation frequency 
is precisely f = 0 or f = 1, the neutral test developed by Williams et al.13 will be correct. However, 
due to the finite resolution with which we can distinguish different mutation frequencies using 
current sequencing techniques, it will be difficult if not impossible to determine that a mutation is 
present at precisely 0 or 1 frequency (e.g. experimental f = 0.9 may correspond to f = 1 due to 
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sequencing errors and vice versa; low frequency mutations may have experimental f = 0 due to 
insufficient sequencing depth). 
 
Our conclusions do not contradict the results of many recent genomic studies that find large 
subclones in majority of sequenced cancers30-32; many of these subclones may in fact be lacking 
functional driver mutations and/or can be a consequence of genetic drift. For example, a recent 
genomic study of chronic lymphocytic leukemia31 (CLL) reports that the majority of macroscopic 
(>10% cancer cell frequency) CLL subclones seem to be passenger subclones that lack selective 
advantage over their parent subclones. Our results are in agreement with the recent Williams et al. 
study15, which found that 21% of colon cancers, 29% of gastric cancers and 53% of metastases 
they examined had evidence of differentially selected (driver) subclones. These estimates are in 
line with our predictions of how likely it would be to detect selection even if 100% of tumors were 
non-neutral.  
 
On the other hand, Nik-Zanai et. al.33 find dominant subclones (>50% CCF) in all 21 breast tumors 
they studied, and argue that these dominant subclones are likely to have been selected (i.e. that 
they are driver subclones). We argue that detecting subclonal drivers is in general challenging; if 
all dominant subclones from Nik-Zanai et al.33 did in fact contain drivers, it may mean that these 
tumors have evolved differently from the model and parameters we have assumed in this paper. 
Yates et al.32 find subclonal driver mutations in 15/50 (30%) of breast cancers they studied; 
Turajlic et al.34 found subclonal driver mutations in 120/216 (56%) of primary and metastatic renal 
cancers they sequenced. The fractions of samples with detectable subclonal driver mutations in 
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these two studies are in line with the average driver detection probability in our model with two 
drivers, which is 43%. 
 
The two-type model we have studied here is a simplification of the process of driver accumulation 
in tumors. Our model is deliberately oversimplified to allow for analytic treatment and to develop 
an intuition why subclonal drivers may elude detection. In reality, detecting subclonal drivers will 
be even more difficult due to experimental uncertainties, confounding passenger mutations, and a 
contribution from contaminating non-cancer cells. For example, we and others13,15 implicitly 
assume that genomic analysis of biopsy samples identifies true cancer cell frequencies of mutations 
in the entire tumor population. However, significant spatial heterogeneity may exist in solid 
tumors, and a minor subclone may be dominant in certain spatial regions of the tumor and 
overrepresented in a tumor biopsy, resulting in possible misleading conclusions derived from the 
mutational frequency spectrum of an unrepresentative sample35.  
 
There is a debate about mini-drivers in cancer36, referring to mutations that are in between strong 
and/or very frequently mutated drivers on the one hand and neutral passenger mutations on the 
other. Our study demonstrates that moderately strong drivers (growth rate increase g=70%) are 
most likely to be detected from macroscopic subclonal frequencies for moderately-growing tumors 
and a typical driver mutation rate (u~10-5). For higher driver mutation rates and/or slower-growing 
tumors, growth advantage of most likely detectable drivers decreases. In particular, our results 
demonstrate that mini-drivers will most likely be detectable in very slow-growing tumors, that are 
already close to or at carrying capacity. 
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Finally, our conclusions are relevant not only to cancer but more generally to the problem of 
measuring selection when an expanding subpopulation of fitter cells coexist with “wild-type” cells, 
such as growing bacterial populations acquiring de novo resistance to antibiotics or adapting to a 
new environment. 
 
MATERIALS AND METHODS 
 
Frequency distribution of a driver subclone 
 
We study a two-type continuous time branching process that starts with a single type-0 cell. With 
rate b, type-0 cells divide into two identical daughter cells. Death rate of type-0 cells is d, with b 
> d. In addition, type-0 cells can receive an additional driver mutation with rate u. We will 
assume that the driver mutation rate is very small, on the order of u ∼ 10−5 (per day). Cells with 
the additional driver divide with rate b1 and die with rate d1, again with b1 > d1. The net growth 
rate of cells with the additional driver, r1 = b1 − d1, is greater than the net growth rate of type-0 
cells, r = b − d. We will denote the ratio of the two growth rates r1 and r by c = r1/r > 1. Let X0 
be the number of type-0 cells at the appearance of the first successful cell with a driver (whose 
progeny survives stochastic fluctuations). The progeny of this cell forms the type-1 population. 
Total population size is the sum of type-0 and type-1 cells.  
 
We are interested in the probability distribution of the fraction fsub of type-1 cells in the 
population when total population size is M. Typical size of M that we will consider is 108 − 109 
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cells. If we let X be the size of the type-0 population and Y the size of the type-1 population when 
total population size is M, then fsub =Y/M and M=X+Y.  
 
Survival probability of a cell with the additional driver mutation is r1/b1 = cr/b1. Thus the "suc- 
cessful" driver mutation rate (the rate at which driver cells with surviving progeny are produced) 
is us = (cr/b1)u. On the other hand, we have shown before that the arrival of mutations which 
appear with rate us in type-0 cells, can be viewed as a Poisson process with rate us/r on the size 
of the type-0 population38. More precisely, we use the fact that the number of mutations 
produced by the type-0 population by the time it reaches population size M is distributed as 
Poisson(M us /r). This result was derived using heuristic arguments by Iwasa et al.
39 and Bozic 
and Nowak38, and proved recently by Cheek and Antal18. The size of the type-0 population when 
the first type-1 cell appears, X0, is therefore exponentially distributed with rate (c/b1)u. Thus X0 
will be of the order of b1/(cu), which is typically much larger than 1, but much smaller than M. 
We note that, in line with multiple studies of similar branching processes40,38, we use a 
continuous approximation to the size of the type-0 population at the time of mutant appearance. 
As typical driver mutation rate is u~10-5, driver mutation is expected to appear when type-0 
population contains ~105 cells, so this approximation is justified. 
 
We will measure time from the appearance of the first type-1 cell. Let t be the time when total 
population size is M. Since X0 is typically very large, the population of type-0 cells at time t can 
be well approximated by X ≈ ert X0. On the other hand, since type-1 cells started a surviving 
population at time 0 with a single cell, for the population of type-1 cells we have40 Y → V1ecrt for 
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large t, where V1 is an exponentially distributed random variable with rate cr/b1. In other words, 
Y ≈ V1 (X / X0)c. It follows that  
𝑀 = 𝑋 + 𝑌 ≈ 𝑋 + 𝑉1(𝑋 𝑋0⁄ )
𝑐 
𝑀1−𝑐 ≈ (𝑋 𝑀)𝑀1−𝑐 + 𝑉1(𝑋 𝑀⁄ )
𝑐⁄ 𝑋0
−𝑐 
1 ≈ (1 − 𝑓𝑠𝑢𝑏) + 𝑉1(1 − 𝑓𝑠𝑢𝑏)
𝑐𝑋0
−𝑐𝑀𝑐−1 
                                                 
𝑓𝑠𝑢𝑏
(1 − 𝑓𝑠𝑢𝑏)𝑐
≈ 𝑉1𝑋0
−𝑐𝑀𝑐−1                                               (3) 
Here we used the fact that X / M = 1 - fsub. On the other hand, 
                                         𝑃[𝑓𝑠𝑢𝑏 ≤ 𝛼] = 𝑃 [
𝑓𝑠𝑢𝑏
(1 − 𝑓𝑠𝑢𝑏)𝑐
≤
𝛼
(1 − 𝛼)𝑐
],                      (4) 
Since x/(1-x)c is a function that increases as x increases from 0 to 1. Thus from (3) and (4) we 
have 
𝑃[𝑓𝑠𝑢𝑏 ≤ 𝛼|𝑋0] ≈ 𝑃 [𝑉1𝑋0
−𝑐𝑀𝑐−1 ≤
𝛼
(1 − 𝛼)𝑐
] 
                              =  𝑃 [𝑉1 ≤
𝛼
(1 − 𝛼)𝑐
𝑋0
𝑐𝑀1−𝑐] 
                              = 1 − exp (−(𝑐𝑟 𝑏1⁄ )
𝛼
(1 − 𝛼)𝑐
𝑋0
𝑐𝑀1−𝑐)                                   (5) 
Finally we have 
         𝑃[𝑓𝑠𝑢𝑏 ≤ 𝛼] ≈ ∫
𝑐𝑢
𝑏1
exp (−
𝑐𝑢
𝑏1
𝑋0) [1 − exp (−
𝑐𝑟
𝑏1
𝛼
(1 − 𝛼)𝑐
𝑋0
𝑐𝑀1−𝑐)]
𝑀
0
𝑑𝑋0      (6) 
We show the excellent agreement of formula (6) and exact computer simulations of the process 
in Fig. 4. 
 
Let 
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𝐻(𝛼) =
𝑐𝑢
𝑏1
exp (−
𝑐𝑢
𝑏1
𝑋0) [1 − exp (−
𝑐𝑟
𝑏1
𝛼
(1 − 𝛼)𝑐
𝑋0
𝑐𝑀1−𝑐)] 
To calculate the probability density function, f, for the frequency of subclonal driver, we note 
that  
𝑓(𝛼) =
𝑑
𝑑𝛼
𝑃[𝑓𝑠𝑢𝑏 ≤ 𝛼] =
𝑑
𝑑𝛼
∫ 𝐻(𝛼)𝑑𝑋0
𝑀
0
 
Using Leibniz’s rule we obtain 
𝑓(𝛼) = ∫
𝑑
𝑑𝛼
𝐻(𝛼)𝑑𝑋0
𝑀
0
 
Finally, probability density function for the frequency of a subclonal driver is given by 
𝑓(𝛼) = (
𝑐
𝑏1
)
2
𝑟𝑢𝑀1−𝑐(1 − 𝛼)−1−𝑐(1
+ (−1 + 𝑐)𝛼) ∫ 𝑋0
𝑐
𝑀
0
exp (−
𝑐
𝑏1
(𝑢𝑋0 + 𝑟𝑀
1−𝑐𝑋0
𝑐(1 − 𝛼)−𝑐𝛼)) 𝑑𝑋0        (7) 
 
Estimating driver mutation rate  
 
The estimated driver mutation rate u ∼ 10−5 used in Fig. 2 comes from Bozic et al.21 In that 
paper, it was estimated that there are 377 driver genes in the human genome, and an average of 
90 positions per driver gene that, if mutated, will result in a functional driver mutation. In 
addition, it was assumed that the mutation rate per base pair per cell division was 5 · 10−10, 
leading to a driver mutation rate on the order of 10−5 per cell division.  
 
Since then, new estimates have become available for both the number of driver genes and the 
point mutation rate in tumors. For example, Vogelstein et al.9 use mutation patterns to estimate 
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that there are 138 driver genes discovered so far. Similarly, Davoli et al.10 use analyzed patterns 
of mutational signatures in tumors and estimate 570 driver genes. Lawrence et al.12 use mutation 
frequencies and estimate 219 driver genes. They also perform a saturation analysis and show that 
many new candidate cancer genes remain to be discovered beyond those they report. Recently, 
Martincorena et al.11 use dN/dS ratio to determine genes under positive selection in cancer and 
estimate 203 driver genes. Based on the sum of these data, we set the upper bound on the number 
of driver genes to be 600.  
 
On the other hand, if we only focus on strong drivers in a single cancer type, such as colorectal, 
the number of genes is significantly smaller. For example, Martincorena et al.11 report 28 genes 
under significant positive selection in colorectal cancer. Thus we will set the lower bound on the 
number of significant driver genes of a single cancer type to 20.  
 
Blokzijl et al.42 estimate that ∼ 40 mutations accumulate per year in the genome of multiple 
human tissues, including the small intestine, colon and liver, leading to a mutation rate of 0.1/day 
per genome or ∼ 4 · 10−11 per base pair per day. This will be our lower bound for the point 
mutation rate. Recently, Werner and Sottoriva43 used the change in the mean and variance of the 
mutational burden with age in healthy human tissues to estimate the mutation rate in the colon 
and small intestine; they obtained ∼ 4 ∗ 10−9 per base pair per cell division. Assuming the value 
they used for time between stem cell divisions is one week, this leads to a mutation rate of ∼ 6 ∗ 
10−10 per base pair per day. Mutation rate in cancer can be increased 10-100 fold compared to 
normal tissues44, so we set the upper bound for point mutation rate to ∼ 100∗6·10−10 = 6·10−8 per 
base pair per day.  
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We obtain an upper bound for the driver mutation rate by multiplying the upper bounds for the 
number of driver genes and point mutation rate with the average number of driver positions, 
leading to uU =600∗6·10−8 ∗90∼10−3 per day.  
 
Multiplying our lower bounds for the number of driver genes and point mutation rate with the 
average number of driver positions leads to the lower bound for the driver mutation rate uL = 
20∗4·10−11 ∗90∼10−7.  
 
Subclonal driver frequency is biased towards 0 and 1 over a large range of parameter 
values  
 
Using formula (6), we numerically evaluate P [0.2 < fsub ≤ 0.8] = F (0.8) − F (0.2) for the 
following ranges of parameters: ratio of net growth rates of cells with and without the driver, c, 
between 1.01 and 3 (i.e. relative growth rate advantage of a driver, g, between 1% and 200%); 
driver mutation rate, u, between 10−7 and 10−3 per day; final tumor size, M , between 107 and 
1011 cells; division rate of cells with the driver, b1, between 0.1 and 1 per day; and net growth 
rate of tumor cells, r, between 0.001 and 0.1 per day. These ranges are wide and include all 
meaningful parameter values.  
 
We create a grid by taking 100 equally-spaced values for each parameter within its range defined 
above (parameter values for driver mutation rate u, tumor size M and net growth rate of tumor 
cells r are equally spaced in log space). We exhaustively evaluate all points on this 5-
dimensional grid (1005 = 1010 parameter value combinations). We find that P [0.2 < fsub ≤ 0.8] < 
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0.6 holds everywhere, and that the frequency of a subclonal driver is always biased toward 0 and 
1.  
 
Computer Simulations 
 
Well Mixed Model: 
 
We perform Monte Carlo simulations of the branching process described in the preceding section 
using the Gillespie algorithm41. We start the simulation with a single type-0 cell. At each 
iteration, time to next event and the type of event are drawn randomly depending on the current 
composition of the population. In particular, cells can die with rate d (type-0 cells) or d1 (type-1), 
divide into two cells with rate b (type-0) or b1 (type-1), or a type-0 cell mutates to type-1 cell 
with rate u. In the simulation, we keep track of the numbers of type-0 cells and of multiple type-1 
populations, until the first type-1 population that is certain to survive stochastic drift appears, at 
which point we only keep track of that type-1 population. We stop the simulation once the total 
population (sum of type-0 and type-1 cells) reaches final size M. We perform between 1000 and 
5000 surviving runs for each parameter combination. 
 
Spatial Model: 
We use the model from our previous work5 but without migration. Cells occupy points on a 3d 
lattice. Each simulation starts from a single cell of type 0. At each time step, a cell either dies 
with rate d (type 0 cell) or d1 (type 1 cell), or replicates with rate b times the fraction of empty 
neighbors. A cell that is completely surrounded by other cells does not replicate. Replication can 
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generate a mutant (type 1 cell) with probability 𝑢/𝑏 (equivalent to the rate of mutant generation 
being 𝑢), where u is the driver mutation rate as in the well-mixed model. Once a mutant has been 
generated, further mutations are forbidden. This is to ensure that only a single driver is present. 
Simulations that do not produce a driver (unlikely) or the population goes extinct due to a 
stochastic fluctuation are rejected. The simulation is stopped when the tumor reaches a given 
final size 𝑀. The fraction of cells with the driver mutation (type 1 cells) is determined, and the 
simulation is repeated 1000 times to obtain the experimental driver frequency distribution. The 
list of driver frequencies is also used as input for the combined 3d-logistic growth model. 
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Figure 1| Schematic representation of the stochastic model of tumor evolution. a, Parental 
cells (blue) divide with rate b, obtain an additional driver with rate u, and die with rate d. Cells 
with the additional driver (red) divide with rate b1 and die with rate d1. The ratio of net growth 
rates of cells with and without the driver, c=(b1-d1)/(b-d) is greater than 1. b, Growth begins with 
a single parental cell. We are interested in the fraction of cells with the driver as a function of the 
total number of tumor cells M. 
 
 
 
 
 
b
b
u
d
b1
d1
a
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Figure 2| Cancer cell frequency of a subclonal driver is biased towards 0 and 1. a, b, c, 
Probability that a subclonal driver is in the detectable range (0.2 ≤ fsub ≤ 0.8) and thus able to 
skew the distribution of mutational cancer cell frequencies expected from neutral evolution for 
three parameter regimes. For each parameter regime, we depict three levels of selection: 
moderate selection (driver increases net growth rate by g = 30%), strong selection (g = 70%), 
and very strong selection (g = 100%). Parameter values for a, moderately growing tumor20: 
b=0.14, r=0.01; b, fast growing tumor37: b=0.25, r=0.07; c, slow-growing tumor21: b=0.33, 
r=0.0013. Driver mutation rate21 u=10-5. All rates are per day and b=b1. d, e, f, Probability 
density for frequency of subclonal driver that increases the net growth rate by 70% in a 
moderately growing tumor (a). d, Driver frequency is biased towards 0 when tumor size is small. 
e, When tumor size is large, driver frequency is biased towards 1. f, When detection is most 
likely (at intermediate size), driver frequency distribution is almost flat.  
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Figure 3| Probability of detection of a subclonal driver for a wide range of driver mutation 
rates and growth rate advantages is always below 60%. Contour plots depict the probability 
that a subclonal driver is in the detectable range (0.2 ≤ fsub ≤ 0.8) and thus able to skew the 
distribution of mutation frequencies expected from neutral evolution, for a, small; b, 
intermediate; and c, large tumor size. Parameter values for moderately growing tumor 
b=b1=0.14, r=0.01. All rates are per day.  
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Figure 4| Comparison of formula for the cumulative distribution of driver frequency and 
exact computer simulations. On the y-axis we plot the probability that driver frequency is 
below a particular value. Error bars are standard errors of the mean (s.e.m.) obtained via 
bootstrapping. Parameters: a, b=b1=0.14, d=0.13, c=1.7, u=10
-5, M=108; b, b=b1=0.14, d=0.13, 
c=1.5, u=10-4, M=108; c, b=b1=0.14, d=0.13, c=1.5, u=10
-5, M=108; d, b=b1=0.14, d=0.17, c=1.9, 
u=10-5, M=108. 
 
 
 
 
 
 
 27 
 
 
 
Supplementary Figure 1| Probability of detection of a subclonal driver in a 3d spatial 
model. Probability that a subclonal driver is in the detectable range (0.2 ≤ fsub ≤ 0.8) for three 
parameter regimes (medium, fast and slow-growing tumor). For each parameter regime, we 
depict three levels of selection: moderate selection (driver increases net growth rate b - d by g = 
30%), strong selection (g = 70%), and very strong selection (g = 100%). Birth rate of all cells5 is 
b=b1=1 (see Materials and Methods for details of the simulation). Death rate of cells without the 
driver5 for a, moderately growing tumor: d=0.7; b, fast growing tumor: d=0.5; c, slow-growing 
tumor: d=0.9. Driver mutation rate u=10-5. All rates are per day. Error bars are s.e.m.  
 
 
 
 
 
 
 
 28 
 
 
 
Supplementary Figure 2| Probability of detection of a subclonal driver in a sigmoidal 
model. Probability that a subclonal driver is in the detectable range (0.2 ≤ fsub ≤ 0.8) for three 
parameter regimes (medium, fast and slow-growing tumor). For each parameter regime, we 
depict three levels of selection: moderate selection (driver increases initial growth rate r by g = 
30%), strong selection (g = 70%), and very strong selection (g = 100%). Parameter values for a, 
moderately growing tumor: r=0.01; b, fast growing tumor: r=0.07; c, slow-growing tumor: 
r=0.0013. Carrying capacity K=1011 cells. Error bars are s.e.m.  
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Supplementary Figure 3| Probability of detection of a subclonal driver in model with two 
sequential drivers. Probability that a subclonal driver is in the detectable range (0.2 ≤ fsub ≤ 0.8) 
for three parameter regimes. Orange line denotes the probability of detection of first driver, and 
blue line represents probability of detection of second driver assuming that first driver is 
undetectable. Red line depicts the probability of detection of any driver (orange + blue). For each 
parameter regime, we depict three levels of selection: moderate selection (first driver increases 
net growth rate r by g = 30%, left), strong selection (g = 70%, middle), and very strong selection 
(g = 100%, right). Second drivers increase the net growth rate by the same absolute amount (gr). 
Parameter values for a, moderately growing tumor: b=0.14, r=0.01; b, fast growing tumor: 
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b=0.25, r=0.07; c, slow-growing tumor: b=0.33, r=0.0013. Driver mutation rate u=10-5. All rates 
are per day and b=b1. 
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